SLC6A3 and autism: Clinical observations suggest that dopamine-blocking antipsychotic drugs reduce repetitive and self-injurious behaviors in autism (Posey et al., 2008) and studies indicate that dopamine transporter binding is significantly higher in the orbitofrontal cortex of autistic adults relative to controls (Nakamura et al., 2010).